Stockreport

Takeda Tests New Highs, But Struggles To Find Entyvio Successor [Seeking Alpha]

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF TAK's Q3 earnings were resilient despite US revenue declining 9.1%; margin improvement and international growth offset generic headwinds. Entyvio remains the key grow [Read more]